Clinical Trials Logo

Cavernoma clinical trials

View clinical trials related to Cavernoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05484245 Recruiting - Clinical trials for Arteriovenous Malformations

Sonography-guided Resection of Brain Mass Lesions

SOMALI
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Objective of the study is to determine possibilities of intraoperative sonography in detecting of various brain mass lesions, assessing extent of their resection and define indications to use ultrasound-guided needle or ultrasound wire-guided port.

NCT ID: NCT05484219 Recruiting - Clinical trials for Arteriovenous Malformations

Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations

FUN
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to assess accuracy, advantages of functional neuronavigation and calculate safe distance from motor areas to brain tumors and vascular malformations in image-guided surgery.

NCT ID: NCT05477680 Recruiting - Clinical trials for Arteriovenous Malformations

Intraoperative Brain Shift Calculation Study

BRASH
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.

NCT ID: NCT03652181 Completed - Clinical trials for Cerebral Cavernous Malformation

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

Start date: August 20, 2018
Phase:
Study type: Observational

Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy. This trial readiness project aims to address current critical obstacles in identifying cases at multiple sites, characterizing their relevant features, and measuring their outcome. The timing cannot be more opportune, with therapeutic targets already identified, exceptional collaboration among researchers and with the patient community, and several drugs ready to benefit from a track to clinical testing in the next five years.